icon- folder.gif   Conference Reports for NATAP  
 
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
 Back grey_arrow_rt.gif
 
 
 
Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results
 
 
  Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
 
there were 2 phase 3 studies presented at IAS, here was the other - IAS: A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)
 
IAS: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17)
 
 Paul E. Sax,1 Anton Pozniak,2 Jose Arribas,3 Ellen Koenig,4 Edwin DeJesus,5 Hans-Jürgen Stellbrink,6 Andrea Antinori,7
Kimberly Workowski,8 Jihad Slim,9 Jacques Reynes,10 Will Garner,11 Devi SenGupta,11 Hal Martin,11 Erin Quirk,11 Andrew Cheng11
 
1Brigham and Women's Hospital, Boston, Massachusetts, USA; 2Chelsea and Westminster Hospital, London, UK; 3Hospital Universitario La Paz, Madrid, Spain; 4IDEV–Instituto Dominicano de Estudios Virologicos, Santo Domingo, Dominican Republic;
5Orlando Immunology Center, Orlando, Florida, USA; 6ICH Study Center, Hamburg, Germany; 7Lazzaro Spallanzani National Institute for Infectious Diseases, Roma, Italy; 8Emory University, Atlanta, Georgia, USA;
9Saint Michael's Medical Center, Newark, New Jersey, USA; 10Gui De Chauliac, Centre Hospitalier Universitaire de Montpellier, France; 11Gilead Sciences, Inc., Foster City, California, USA

IAS1

IAS2

IAS3

IAS4

IAS5

References
1. AIDSinfo. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf;
2. EACS. http://www.eacsociety.org/files/guidelines_8.2-english.pdf;
3. Gunthard HF, et al. JAMA 2016;316:191-210;
4. Arribas JR, et al.
J Acquir Immune Defic Syndr 2017;75:211-8;
5. Gallant JE, et al. J Acquir Immune Defic Syndr 2017;75:61-6;
6. Tsiang M, et al. Antimicrob Agents Chemother 2016.60:7086-97;
7. Sax PE, et al. Lancet HIV 2017;4:e154-60.